TABLE 4.

Five-year survival estimates by patient and clinical characteristics

Characteristic	n	DMFS		OS
		5-Year estimate (95% CI)	P-value	5-Year estimate (95% CI)	P-value
All	1325	0.61 (0.58, 0.64)		0.68 (0.66, 0.71)
Operative treatment
BCT	651	0.68 (0.64, 0.71)		0.74 (0.7, 0.77)
Mastectomy	674	0.54 (0.50, 0.58)	<0.0001	0.63 (0.59, 0.67)	<0.0001
Age
≤50 years	813	0.58 (0.55, 0.62)		0.67 (0.63, 0.7)
>50 years	512	0.66 (0.61, 0.7)	0.001	0.71 (0.66, 0.75)	0.44
Race
Nonblack	1140	0.61 (0.58, 0.64)		0.69 (0.66, 0.71)
Black	185	0.61 (0.53, 0.68)	0.79	0.66 (0.58, 0.72)	0.12
Tumor size
T1	642	0.71 (0.67, 0.75)		0.78 (0.74, 0.81)
T2–4	683	0.51 (0.47, 0.55)	<0.0001	0.59 (0.56, 0.63)	<0.0001
Lymph nodes
N0	687	0.7 (0.66, 0.73)		0.78 (0.74, 0.81)
N1–3	638	0.52 (0.48, 0.56)	<0.0001	0.58 (0.54, 0.62)	<0.0001
Nuclear grade
I or II	144	0.68 (0.59, 0.75)		0.75 (0.67, 0.82)
III	1111	0.60 (0.57, 0.63)	0.10	0.67 (0.64, 0.69)	0.02
LVI
Negative/unknown	888	0.69 (0.66, 0.72)		0.75 (0.71, 0.78)
Positive	426	0.44 (0.39, 0.49)	<0.0001	0.55 (0.5, 0.6)	<0.0001
Resection margins
Free	1210	0.62 (0.59, 0.65)		0.69 (0.66, 0.72)
Positive/close	94	0.48 (0.37, 0.58)	0.001	0.58 (0.47, 0.68)	0.013
Surgical date
1980–2000	715	0.60 (0.56, 0.63)		0.69 (0.66, 0.73)
2000–2007	610	0.63 (0.59, 0.67)	0.35	0.67 (0.63, 0.71)	0.10
Adjuvant radiation
No	471	0.58 (0.54, 0.63)		0.65 (0.6, 0.69)
Yes	852	0.62 (0.59, 0.66)	0.054	0.70 (0.67, 0.74)	0.048
Adjuvant chemotherapy
Anthracycline and taxane based	521	0.58 (0.53, 0.62)		0.63 (0.59, 0.67)
Anthracycline or taxane based	638	0.66 (0.62, 0.7)		0.72 (0.69, 0.76)
Non-anthracycline/taxane based	166	0.53 (0.45, 0.61)	<0.0001	0.69 (0.61, 0.76)	0.002